Stop overconsuming content on India-Pakistan conflict to avoid anxiety: Experts
'Just like Covid-19, precautions should be taken to deal with a war-like situation. Consumption of misinformation and content related to the conflict can lead to anxiety. It may even affect the ability of people to act and implement precautions,' said Dr C J John, a Kochi-based psychiatrist.
The misinformation can create a deeper impact, especially in children and the senior population, who are more vulnerable. 'Children are not aware of the realities on the ground. So they may panic, thinking that it would consume them all. The elderly are not used to the information-overload. Thus, they may take the information seriously, which will end up affecting their mental health,' said Dr Arun B Nair, associate professor of psychiatry at Thiruvananthapuram Government Medical College Hospital.
Family members should constantly reassure children, the elderly, and those who are susceptible to anxiety disorders. 'We need to support them. They should not be watching news and visuals constantly. We need to cut down on misinformation. Listening to daily briefings or advisories issued by the government can help understand developments. It helps in adhering to instructions,' he said.
With the exchange of hostilities occurring mostly after sundown, watching news and visuals late at night can affect sleep, leading to stress and anxiety issues. 'Some may experience panic attacks, sudden and intense restlessness, breathlessness, sweating, and a feeling of losing their mind. It may persist for 10-15 minutes and occur repeatedly. This can result in insomnia,' Dr Arun said.
He added that youngsters and people who actively engage on social media should refrain from spreading misinformation. 'Though the conflict is a new experience for youngsters, they are aware of what is happening with Israel, Gaza and Ukraine. So, there is some desensitisation happening. Do not spread messages harming the state and affecting communal harmony,' he emphasised.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Wadia doc helps 40 kids with genetic disease get 1cr/yr US drug free for life
Mumbai: Early Monday morning, 14-year-old Bhavin Khare and his mother, Tanuja, set off from Thane's Murbad for Wadia Hospital, Parel, around 100km away, with a sense of anticipation. They had to collect a US drug—estimated to cost over Rs 1 crore for a year's supply—that would help him control the debilitating symptoms of cystic fibrosis, a genetic disease he suffers from. "Bhavin has been struggling all his life. He manages to go to school only 50% of the days due to repeated cough and chest infections," Tanuja said, hoping the new drug would let him lead a "normal life". He is one of five children with cystic fibrosis who received a three-month supply of Trikafta, manufactured by US-based Vertex Pharmaceuticals, at the hospital Monday. Thirty-five others are scheduled to get it in the coming days. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai "We have signed an MoU with the company which, on compassionate grounds, will provide a lifelong supply of Trikafta to 40 patients," said pulmonology department head Dr Parmarth Chandane, who communicated with the US company for almost a year. Due to patent laws, the drug isn't available in India and can only be imported. Affected children in wealthy nations have had access to the drug for almost eight years, and parents' groups in Karnataka, South Africa and Brazil have moved local courts seeking some mechanism like compulsory licensing to ensure their children get access to the drug, too. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Libas Purple Days Sale Libas Undo "The active ingredients for the three-drug combination (Trikafta—elexacaftor/tezacaftor/ivacaftor) that is now being called a miracle, are made in India, but our children don't have access to the finished product," said a doctor who didn't want to be identified. The Wadia Hospital distribution is the beginning of an alternative access for Indian patients. "The drug has shown promise, with certain research reports claiming patients will be able to enjoy a normal lifespan of 80 years as against the 15-20 years one normally associates with the disease," said Dr Chandane, who communicated with the US company for almost a year, seeking access for the 80 patients registered at Wadia Hospital. The company, however, said it would only provide drugs for patients over six years of age, resulting in only 40 qualifying for the free-for-life supply. Each of the affected children has to take three drugs—two in the morning and one in the evening—daily to prevent the buildup of thick, sticky mucus that usually clogs organs such as the lungs, pancreas and intestines, which could further lead to malnutrition, poor growth, frequent respiratory infections, as well as chronic lung disease. It's learnt that Vertex Pharmaceuticals will provide lifelong supply of the drug to patients registered at CMC Vellore in Tamil Nadu, too. "We are also in talks with the company for our patients," said paediatrician Dr Indu Khosla from SRCC Hospital, Haji Ali. "By offering such costly and essential medication free of charge, we're removing financial barriers for families. These children are getting a chance to breathe easier, grow healthy and live longer," said Dr Minnie Bodhanwala, CEO of Bai Jerbai Wadia Hospital for Children.
Hindustan Times
5 hours ago
- Hindustan Times
Death of 6-year-old Delhi girl due to rabies sparks outrage, locals slam MCD
The death of a six-year-old girl, Chhavi, due to rabies after a dog bite has sparked outrage in the Pooth Kalan area in Delhi's Rohini. The residents claim that the MCD officials began removing canines from the street only after the Supreme Court took suo motu cognisance of the incident. The Supreme Court on Monday highlighted the increasing cases of dog bite in Delhi that leads to rabies, impacting the vulnerable population.(Pixaby/Representational Image) 'Why did it take a child's death and a Supreme Court order for anyone to care', family of the six-year-old asked. The Supreme Court on Monday highlighted the increasing cases of dog bite in Delhi that leads to rabies, impacting the vulnerable population, including children and the elderly. 'We take suo motu cognisance of this news item,' the court said, according to PTI news agency. The court ordered the register of the death of the girl as a public interest matter. Six-year-old Chhavi Sharma, who was affectionately called 'Bittu' by her family, was bitten by a stray dog on June 30 while going to her aunt's house in the same area. According to the family, the dog attacked her without any provocation. The family found out about the bite when Chhavi came crying and bleeding to the aunt and collapsed on the doorstep. 'We washed her wounds and immediately took her to the Dr BR Ambedkar Hospital, where her anti-rabies treatment began,' the girl's aunt, Krishna Devi, told PTI. Doctors administered her first vaccine dose and scheduled the remaining doses for July 3, 7 and 28. However, Chhavi's condition worsened by mid-July when she started vomiting while in school on July 21. That night, the six-year-old lost strength in her limbs and stopped speaking, after which the family took her to a private hospital where doctors suspected rabies. Just a few days before her final dose of the vaccine, Chhavi died on July 25. Chhavi's family alleged medical negligence from the first hospital, stating that despite the first visit, she could not even lift her hand by the second week. The family alleged that even when they kept going back, the hospital refused to pay attention. "Had they paid attention, maybe our daughter would have been alive today,' Krishna Devi said. Chhavi, who lost her mother as a baby during the Covid-19 pandemic, was raised by her paternal uncle and aunt. She brought life into the home, her family said, 'but after her death, now there is silence." Stray dogs bit at least 4 people before This was not the first incident of a dog bite. Pooth Kalan residents say that they have filed multiple complaints about the stray dogs in the area, but no one has paid any attention. 'The dog bit at least four to five people before her,' a relative said. Residents say that now that a child has lost her life, MCD has suddenly started removing dogs. Locals say that the unregulated feeding of the stray dogs by outsiders worsens the issue. They say that these dogs become territorial and start chasing children. Former Union Minister Vijay Goel welcomed the SC move and said that he will present facts and public grievances before the court. According to him, more than 2.000 dog bite cases are reported in Delhi every day. Seeing the menace, MCD recently formed a subcommittee to set up shelter homes for these dogs in each city zone. The committee, chaired by Satya Sharma, will prepare an action plan to identify sites, estimate the budget and coordinate with NGOs to set up shelters.
Time of India
6 hours ago
- Time of India
Maker of GLP1 pens scales up for generic debuts
As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, anticipates significant growth. Its stock has nearly doubled, and the company is doubling its production capacity to 80-85 million pens by fiscal year-end to meet rising domestic and export demands. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: With sales of weight-loss drugs surging and set to go up even more as semaglutide goes off patent early next year, a low-profile manufacturer of injector pens, Gujarat-based Shaily Engineering Plastics , is set to reap a windfall. Its stock has nearly doubled over the past 12 months. Manufacturers of the pen-like devices that make it easy to self-administer metered doses that would otherwise need to be injected with a syringe are the unnoticed beneficiaries of weight-loss drugs becoming is doubling capacity in line with plans of top pharma companies to launch generic versions of GLP1 weight-loss drugs early next year in India and overseas, said a senior company executive. It will be increasing capacity to 80-85 million pens by this fiscal year end from 40-45 million currently to cater to domestic and export demand, Sanjay Shah, chief strategy officer, told ET."We will look at further expansion and ramp up (in FY27). Currently, we are working with multiple players who are looking to launch generic semaglutide in different markets," he to Shah, various estimates suggest global demand for injector pens is likely to reach 500 million per year in the next two-three years and about 2 billion by is leading industry insiders to predict a looming supply crunch for pen leading drugmakers like Sun Pharma , Dr Reddy's, Cipla and Lupin are expected to be a part of the first-day launch wave in several international markets and India as soon as the patent is investing about '125 crore in FY26 on capacity expansion of its IP-led pen platform."We will be expanding (capacity) going forward to cater to the global as well as domestic market," said drugmaker Novo Nordisk 's weight-loss molecule semaglutide, branded Ozempic and Wegovy , will go off patent in March next year, opening up the gates for Indian and overseas drugmakers to launch cheaper generic expect an immediate price reduction of 50% and further by 60-80% over the coming years. This will boost affordability, potentially spurring sales of the drug and consequently, injector the past, shortages of both Eli Lilly's tirzepatide and Novo's semaglutide in the US were largely due to lack of devices and fill-n-finish capacities after demand for the drugs far outstripped supply.
